Mackenzie Financial’s BridgeBio Pharma BBIO Stock Holding History

Mackenzie Financial’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.2M	Buy	298,440 +191,529	+179%	+$13.4M	0.02%	419
2026 Q1	$7.94M	Buy	106,911 +52,416	+96%	+$3.8M	0.01%	568
2025 Q4	$4.11M	Buy	54,495 +4,448	+9%	+$292K	﹤0.01%	685
2025 Q3	$2.6M	Buy	50,047 +21,657	+76%	+$1.06M	﹤0.01%	764
2025 Q2	$1.23M	Buy	28,390 +9,274	+49%	+$337K	﹤0.01%	960
2025 Q1	$661K	Buy	19,116 +9,611	+101%	+$324K	﹤0.01%	1105
2024 Q4	$261K	Buy	9,505 +592	+7%	+$15.3K	﹤0.01%	1442
2024 Q3	$227K	Buy	+8,913	New	+$234K	﹤0.01%	1322
2024 Q2	–	Sell	-6,992	Closed	-$216K	–	1546
2024 Q1	$216K	Hold	6,992	–	–	﹤0.01%	1310
2023 Q4	$282K	Buy	+6,992	New	+$210K	﹤0.01%	1180
2021 Q4	–	Sell	-6,277	Closed	-$294K	–	1438
2021 Q3	$294K	Buy	6,277 +2,625	+72%	+$141K	﹤0.01%	1146
2021 Q2	$223K	Buy	+3,652	New	+$209K	﹤0.01%	1145

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Mackenzie Financial's BBIO Position: Q2 2026 in Review

Mackenzie Financial increased its BridgeBio Pharma (BBIO) stake by 179% in Q2 2026, buying an estimated $13.4M and bringing the position to 298,440 shares worth $22.2M. The position accounts for 0.02% of the portfolio, ranked #419.

Mackenzie Financial first reported a position in BBIO in Q2 2021 and has held it in 12 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Mackenzie Financial held 298,440 shares of BridgeBio Pharma worth $22.2M as of Q2 2026.
Mackenzie Financial bought 191,529 BridgeBio Pharma shares in Q2 2026, an estimated $13.4M.
BridgeBio Pharma made up 0.02% of Mackenzie Financial's portfolio in Q2 2026, its #419 holding.
Mackenzie Financial first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 12 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.